Publication: Promising Response of Paclitaxel in Metastatic Transitional Cell Carcinoma of Distal Ureter Complicated with Hydroureteronephrosis: A Case Report
| creativeworkseries.issn | JNMA Print ISSN: 0028-2715; Online ISSN: 1815-672X | |
| dc.contributor.author | Khan, Sajjad Ahmed | |
| dc.contributor.author | Sah, Santosh | |
| dc.contributor.author | Parajuli, Surya Bahadur | |
| dc.contributor.author | Sapkota, Sulav | |
| dc.contributor.author | Rayamajhi, Asmita | |
| dc.date.accessioned | 2025-09-28T07:13:29Z | |
| dc.date.available | 2025-09-28T07:13:29Z | |
| dc.date.issued | 2023 | |
| dc.description | Sajjad Ahmed Khan Birat Medical College and Teaching Hospital, Biratnagar, Morang, Nepal Santosh Sah Birat Medical College and Teaching Hospital, Biratnagar, Morang, Nepal Surya Bahadur Parajuli Department of Community Medicine, Birat Medical College and Teaching Hospital, Biratnagar, Morang, Nepal Sulav Sapkota Department of Medical Oncology and Haematology, Birat Medical College and Teaching Hospital, Biratnagar, Morang, Nepal Asmita Rayamajhi Department of Medical Oncology and Haematology, Birat Medical College and Teaching Hospital, Biratnagar, Morang, Nepal | |
| dc.description.abstract | Abstract Ureteric carcinoma is the rarest of all urothelial malignancies, and little attention has been given to it. Palliation in these groups of patients is a dilemma in the clinics. Use of chemotherapeutic agents in ureteric carcinoma is a double edged sword, as these patients had already impaired renal function due to post-renal failure and nephrotoxic nature of most of the chemotherapeutic agents can further deteriorate the renal function, making the management approach, a relatively visionary task. Here, we present a case of a 77-year-old female with metastatic ureteric carcinoma locally complicated with hydroureteronephrosis, coming to us with gross haematuria, lower abdominal pain along with cough. Apart from age factor of the lady, presence of hydroureteronephrosis and pulmonary metastases was another challenge for us. Paclitaxel remains the mainstay of our treatment. | |
| dc.identifier | https://doi.org/10.31729/jnma.8072 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/2428 | |
| dc.language.iso | en_US | |
| dc.publisher | Nepal Medical Association | |
| dc.subject | Carcinoma | |
| dc.subject | Case reports | |
| dc.subject | Metastasis | |
| dc.subject | Paclitaxel | |
| dc.title | Promising Response of Paclitaxel in Metastatic Transitional Cell Carcinoma of Distal Ureter Complicated with Hydroureteronephrosis: A Case Report | |
| dc.type | Other | |
| dspace.entity.type | Publication | |
| local.article.type | Case Report | |
| oaire.citation.endPage | 279 | |
| oaire.citation.startPage | 277 | |
| relation.isJournalIssueOfPublication | 1a48971b-f01c-4cb6-9e15-badb9467396e | |
| relation.isJournalIssueOfPublication.latestForDiscovery | 1a48971b-f01c-4cb6-9e15-badb9467396e | |
| relation.isJournalOfPublication | e6e146a0-0ece-4aba-aa0a-6ccfbd10a12a |